This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Zynlonta (loncastuximab tesirine-lpyl)
General Description
Zynlonta (loncastuximab tesirine-lpyl) is a prescription medicine used to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more previous systemic therapies. It is a targeted antibody-drug conjugate designed to attack lymphoma cells while limiting damage to healthy cells.
Getting Zynlonta (loncastuximab tesirine-lpyl) in India
Zynlonta (loncastuximab tesirine-lpyl) is approved in countries such as the United States and Europe but is not currently commercially available in India. Eligible patients may access the medicine through the Named Patient Program (NPP).
MitoGENE helps patients and healthcare providers obtain Zynlonta legally and safely by assisting with documentation, regulatory approvals, import coordination, and delivery under physician supervision.
Disease Indications: Lymphoma
Manufacturer: ADC Therapeutics
Usage: Intravenous
Medicine Approved by:
- European Medical Agency (EMA)
- Food and Drug Administration (FDA)
Available Dosage Form & Package:
- Single-dose vial One vial of 10 mg
Shipping: Cold Chain Shipping
Zynlonta requires temperature-controlled shipping to maintain its quality and effectiveness. Specialized medical couriers use validated cold chain packaging and handling procedures to ensure safe delivery. Due to these requirements, shipping costs may be higher than standard pharmaceutical shipments.
Four Simple Steps to Access Zynlonta (loncastuximab tesirine-lpyl)
If Zynlonta (loncastuximab tesirine-lpyl) is not yet approved or available commercially in your country, MitoGENE can help you access it through a legal pathway. Here’s how:
